Rankings
▼
Calendar
TSHA (Taysha Gene Therapies, Inc.) Stock Financials & Earnings | Market Cap Arena
TSHA
Taysha Gene Therapies, Inc.
Mkt Cap
$1B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$6M
Net Income (TTM)
-$100M
EPS (TTM)
-$0.35
Free Cash Flow (TTM)
-$85M
Gross Margin
95.5%
Op. Margin
-1618.5%
Net Margin
-1583.7%
FCF Margin
-1349.6%
P/S Ratio (TTM)
175.4x
P/E Ratio (TTM)
—
YoY Rev Growth
-36.4%
Employees
—
Earnings Reports
▶
Q3 2025
Browse All Reports
Next: Q4 2025 · Mar 11
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q4 22
$3M
$823K
-$19M
Q1 23
$5M
$4M
-$17M
Q2 23
$2M
$2M
-$23M
Q3 23
$5M
$4M
-$16M
Q4 23
$4M
$4M
-$16M
Q1 24
$3M
$3M
-$24M
Q2 24
$1M
$1M
-$21M
Q3 24
$2M
$2M
-$26M
Q4 24
$2M
$2M
-$20M
Q1 25
$2M
$2M
-$21M
Q2 25
$2M
$2M
-$27M
Q3 25
$0
-$286K
-$34M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q4 22
442.4x
—
Q1 23
153.6x
—
Q2 23
115.3x
—
Q3 23
77.1x
—
Q4 23
71.6x
—
Q1 24
78.2x
—
Q2 24
86.0x
—
Q3 24
111.6x
—
Q4 24
132.8x
—
Q1 25
153.2x
—
Q2 25
136.7x
—
Q3 25
175.4x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q4 22
$14M
$12M
Q1 23
-$20M
-$24M
Q2 23
-$19M
-$19M
Q3 23
-$18M
-$21M
Q4 23
-$16M
-$16M
Q1 24
-$20M
-$20M
Q2 24
-$22M
-$22M
Q3 24
-$22M
-$22M
Q4 24
-$18M
-$18M
Q1 25
-$22M
-$22M
Q2 25
-$20M
-$20M
Q3 25
-$24M
-$24M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q4 22
$2M
Q1 23
$4M
Q2 23
$0
Q3 23
$4M
Q4 23
$17K
Q1 24
$140K
Q2 24
$201K
Q3 24
$35K
Q4 24
$2K
Q1 25
$378K
Q2 25
$2K
Q3 25
$108K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q4 22
—
-57.4%
Q1 23
—
-57.2%
Q2 23
—
-22.8%
Q3 23
—
-19.9%
Q4 23
+44.0%
-6.4%
Q1 24
-27.5%
+30.5%
Q2 24
-53.6%
-13.1%
Q3 24
-62.3%
+35.8%
Q4 24
-43.9%
+10.6%
Q1 25
-32.5%
-14.5%
Q2 25
+78.6%
+28.2%
Q3 25
-100.0%
+22.9%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q4 22
$4M
164.0%
Q1 23
$2M
35.6%
Q2 23
$2M
92.8%
Q3 23
$2M
43.0%
Q4 23
$2M
54.6%
Q1 24
$3M
93.8%
Q2 24
$3M
299.6%
Q3 24
$3M
187.8%
Q4 24
$3M
159.1%
Q1 25
$3M
143.1%
Q2 25
$3M
160.6%
Q3 25
$3M
—
marketcaparena.com
OpEx Breakdown
R&D
G&A
SG&A
Quarter
R&D
G&A
SG&A
Q4 22
$14M
—
$6M
Q1 23
$13M
—
$8M
Q2 23
$20M
—
$5M
Q3 23
$12M
—
$8M
Q4 23
$13M
$7M
—
Q1 24
$21M
$7M
—
Q2 24
$15M
$7M
—
Q3 24
$15M
$8M
—
Q4 24
$15M
$7M
—
Q1 25
$16M
$8M
—
Q2 25
$20M
$9M
—
Q3 25
$25M
$8M
—
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q4 22
$88M
$0
$88M
Q1 23
$63M
$0
$63M
Q2 23
$45M
$0
$45M
Q3 23
$164M
$0
$164M
Q4 23
$144M
$0
$144M
Q1 24
$124M
$0
$124M
Q2 24
$173M
$0
$173M
Q3 24
$158M
$0
$158M
Q4 24
$139M
$0
$139M
Q1 25
$117M
$0
$117M
Q2 25
$313M
$0
$313M
Q3 25
$297M
$0
$297M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q4 22
56M
+37.7%
Q1 23
63M
+12.2%
Q2 23
64M
+1.6%
Q3 23
126M
+95.7%
Q4 23
187M
+48.7%
Q1 24
231M
+23.7%
Q2 24
233M
+0.7%
Q3 24
268M
+15.0%
Q4 24
205M
-23.5%
Q1 25
269M
+31.4%
Q2 25
298M
+10.7%
Q3 25
353M
+18.6%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 19
—
—
FY 20
$0
38
FY 21
$0
178
FY 22
$38K
65
FY 23
$297K
52
FY 24
$114K
73
marketcaparena.com